Olema Pharmaceuticals, Inc.OLMA

Olema Pharmaceuticals, Inc. lost $53.1 million in net income and $58.0 million in operating income for the quarter ending March 31, 2026, while burning $46.0 million in operating cash and holding $52.5 million in cash and cash equivalents. The company’s stockholders’ equity stood at $480.5 million, but with 102.8 million diluted shares outstanding and a diluted loss per share of $0.52, the equity cushion is more of an accounting artefact than a source of strength. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1750284/000165495026000130/0001654950-26-000070-index.htm)

Olema is a clinical-stage oncology company focused on developing targeted therapies for breast cancer and other endocrine-driven cancers, with a pipeline anchored by palazestrant, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) designed to block both AF1 and AF2 transcriptional activation domains. The company’s lead programme is in metastatic breast cancer, and it is also advancing OP-3136, a KAT6 inhibitor, which recently showed preliminary clinical data at the 2026 ASCO Annual Meeting. Separately, Olema entered a clinical trial collaboration and supply agreement with Bayer in May 2026 to evaluate OP-3136 in combination with NUBEQA (darolutamide) in metastatic castration-resistant prostate cancer, with the study expected to start in the second half of 2026. (source: Clinical Trials | Advancing Breast Cancer Care at Olema, https://olema.com/clinical-trials/; Pipeline | Novel Breast Cancer Therapies in Development, https://olema.com/pipeline/; Press Release, 2026-05-26, https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/olma-ex99_1.htm)

The balance sheet itself is a study in contrasts. Total assets were $530.6 million at March 31, 2026, but liabilities were a modest $50.2 million, leaving shareholders’ equity at $480.5 million. The cash position, at $52.5 million, is real, but the path from preclinical science to commercial revenue remains unproven. Research and development expense for the quarter was $49.2 million, nearly matching the quarter’s cash burn, while net cash used in operating activities was $46.0 million. Diluted loss per share was $0.52 on 102.8 million diluted shares, a figure that would look familiar to any shareholder watching the dilution creep in quarter after quarter. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1750284/000165495026000130/0001654950-26-000070-index.htm)

There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The company’s market capitalisation cannot be calculated directly from the evidence, but with 102.8 million diluted shares outstanding and a net loss per share of $0.52, the equity’s value is tied to the success or failure of its lead programmes rather than to any trading momentum. The absence of revenue, operating income, or cash flow guidance in the filings means the market’s valuation is effectively a bet on clinical outcomes, with the clock ticking on the $52.5 million cash runway. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1750284/000165495026000130/0001654950-26-000070-index.htm)

The company’s latest 8-K filing on June 23, 2026, confirms the annual meeting of stockholders but does not disclose any material updates on revenue, cash flow, or guidance. The clinical pipeline remains the primary driver of valuation, with palazestrant and OP-3136 the headline assets, but neither has yet produced revenue or definitive Phase III data. The collaboration with Bayer is a non-dilutive financing tool rather than a revenue stream, and while it extends the runway conceptually, it does not change the current financial trajectory. The company’s investor relations page and pipeline materials are the only public sources for programme updates, and these do not substitute for audited financials or clinical readouts. (source: OLMA SEC EDGAR 8-K, 2026-06-23, https://www.sec.gov/Archives/edgar/data/1750284/000119312526279483/olma-20260617.htm)

What would change the file? A Phase III readout for palazestrant in metastatic breast cancer, or interim data from the OP-3136 study, would materially alter the risk-reward profile. Until then, the company’s equity story is a clinical bet dressed in accounting language, with the balance sheet serving as the most concrete artefact of its current state. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1750284/000165495026000130/0001654950-26-000070-index.htm)